Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069906 | 0.89 | CMA1 (0.41) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL24409891 | 0.88 | TUBB1 (0.37) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL57624 | 0.84 | KMT2A (0.43) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL13681963 | 0.84 | KMT2A (0.43) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL22069908 | 0.84 | TUBB1 (0.54) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL22069907 | 0.84 | TUBB1 (0.54) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL20732484 | 0.84 | TUBB1 (0.54) | TUBB1KMT2APOLBMEN1SMN1; SMN2 | |
| SCHEMBL22316484 | 0.81 | TUBB1 (0.40) | TUBB1 | |
| SCHEMBL22111332 | 0.81 | TUBB1 (0.40) | TUBB1 | |
| SCHEMBL20732319 | 0.81 | TUBB1 (0.37) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-3666787-B9 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| WO-2019031614-A1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | 大日本住友製薬株式会社 | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885KMT2A 3110/4885POLB 4410/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885KMT2A 3110/4885POLB 4410/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885KMT2A 2112/4885POLB 4594/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885KMT2A 2112/4885POLB 4594/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885KMT2A 2112/4885POLB 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.